U.S. and EU-5 Prefilled Syringes Small Molecules Market to reach US$ 17.1 Billion by 2024; U.K. Market to Witness Highest Growth rate During the Forecast Period

According to the report, the U.S. and EU-5 Prefilled Syringes Small Molecule Market was valued at US$ 9.15 Bn in 2015 and is projected to expand at a CAGR of 6.0 % to 8.0 % from 2016 to 2024 to reach US$ 17.1 Bn in 2024. This report offers a thorough understanding of the U.S. and EU-5 prefilled syringes small molecule market, its key trends, drivers, restraints, and opportunities.

The current prefilled syringes small molecule market worldwide, of which the U.S. and EU-5 collectively hold over 76% share, is driven by a rise in the prevalence of metabolic and lifestyle diseases, availability of generic equivalents and growing demand for safe and easy drug delivery. Germany is the biggest market in EU-5 region followed by UK for many key players operating in the prefilled syringes small molecule domain, while the U.S. has been the biggest value market. However, with an increasing demand for safety and ease of drug delivery, inclination towards self-medication for emergency situations, awareness for PFS small molecules in emergency situations, UK is expected to witness a promising CAGR shifting toward value growth by the end of the forecast period. In 2015, the U.S. dominated the U.S and EU-5 prefilled syringes small molecule market, representing a significant market size of nearly 144 million units. The prefilled syringes small molecule market in EU5, on the other hand, represented a smaller share of the total U.S and EU-5 prefilled syringes small molecule market. However, it is set to create a sizeable incremental dollar opportunity in the period from 2016 to 2024, owing to an exponential growth rate. This high growth rate, coupled with increasing foray of generic drug equivalents in the market compared to the U.S., make EU-5 an attractive market for investment.

Get Exclusive Sample Copy of Report – http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16988

The opportunities are growing in the prefilled syringe small molecule market as huge companies are focusing on contract manufacturing outsourcing (CMO) and key market players are involved in developing new products to treat asthma better. The key pharmaceutical supplier are also focusing on widening their footprint in prefilled syringe small molecules with acquisition of small players, acquisition of PFS small molecule brands from other players. According to a key opinion leader from a leading organization in the prefilled syringe small molecule market, the challenge in the market has been inadequate product quality and inaccuracy in dose leading to recall of prefilled syringe small molecule products. Thus, maintaining the product efficacy and correct dose in prefilled syringe and insisting upon adherence to drug administration laws are the areas where companies have realized that quality plays a major role.

In the U.S., a key trend in the market has been a rise of generic equivalent availabilities and market exclusivity agreements. Although the generic equivalent availability is comparatively better in the U.S. compared to EU-5, most key players operating in this market believe that further increasing foray of small molecules owing to patent expiry and generic equivalents availability is the key to grow prefilled syringe small molecule market. For instance, Sandoz launched a glatiramer acetate prefilled syringe by name Glatopa, an equivalent to branded Copaxone. The global annual prefilled syringe market has been estimated to be over US$ 34.86 Bn. This includes both small molecules and large molecule prefilled syringes. The prefilled syringe small molecule market was US$ 12.03 Bn. Moreover, many small and big players have recognized  vast potential in prefilled syringe small molecules owing to patent expirations and demand for safety and accuracy of drug dosage delivery. The market for neurological and cardiovascular small molecule drug prefilled syringe is growing faster in the U.S. compared to the market for other small molecule prefilled syringe.

Major companies competing in the prefilled syringe small molecule market, and profiled in the report, include Teva Pharmaceutical Industries Ltd., Hospira, Inc (Now Pfizer, Inc.), Mylan N.V., Fresenius Kabi, Becton, Dickinson and Company and Sanofi.

The U.S. and EU-5 prefilled syringe small molecule market has been segmented as follows:

U.S. and EU-5 Prefilled Syringe Small Molecule Market, by Therapeutic Class

Neurology

  • Glatiramer Acetate

Cardiovascular Drugs

  • Atropine Sulfate
  • Furosemide
  • Verapamil Hydrochloride
  • Amiodarone
  • Epinephrine/Adrenaline
  • Enoxaparin sodium
  • Fondaparinux Sodium
  • Nadroparin Calcium
  • Dalteparin
  • Ephedrine

Analgesics

  • ketorolac Tromethamine
  • Morphine Sulphate
  • Dexamethasone Na Po4
  • Hydromorphone Hydrochloride

Adjuvants

  • Water for Injection
  • NaCl 0.9%/Saline
  • HPMC
  • Sodium Hyaluronate
  • 25% Dextrose

Others

  • Diphenhydramine
  • Midazolam
  • Lidocaine Hydrochloride
  • Penicillin
  • Metoclopramide
  • Ondansetron
  • Methotrexate
  • Fibrin Sealant
  • Gadobutrol

View Report Press Release – http://www.transparencymarketresearch.com/pressrelease/us-eu5-prefilled-syringe-small-molecule-market.htm

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

VN:F [1.9.22_1171]
Rating: 5.0/5 (1 vote cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)
U.S. and EU-5 Prefilled Syringes Small Molecules Market to reach US$ 17.1 Billion by 2024; U.K. Market to Witness Highest Growth rate During the Forecast Period, 5.0 out of 5 based on 1 rating

No comments.

Leave a Reply

You must be logged in to post a comment.